Genetically-Modified Lymphocytes for Solid Tumor Persistence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adoptive cell transfer therapies for cancer treatment face challenges such as short-term survival of transferred cells and inefficiencies in navigating and persisting within the immunosuppressive tumor microenvironment, particularly in solid tumors.
Innovation Solution
Genetically-modified lymphocytes expressing multiple transgenes, including cytokines, decoys, and cellular elimination tags, are developed to modulate the immune system and enhance persistence and efficacy within the tumor microenvironment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adoptive cell transfer therapy is used to treat cancer, then immune response against tumor is enhanced, but the transferred cells have short-term survival in the tumor microenvironment
Solution Approach 1:
The lymphocytes are pre-engineered with multiple transgenes (IL-2, PD-1 decoy, tEGFR) before transfer, equipping them with self-sufficiency for survival and function in the tumor microenvironment. This preliminary genetic modification enables the cells to produce their own growth factors and resist immunosuppression, directly addressing the short survival time issue while maintaining effective immune response.
Solution Approach 2:
The genetically-modified lymphocytes become self-sufficient by producing their own IL-2 growth factor through the transgene, eliminating dependence on external cytokine support. The PD-1 decoy provides self-protection against immunosuppressive signals in the tumor microenvironment, allowing the cells to sustain their anti-tumor activity long-term without external intervention.
2Duration of action of moving object
If lymphocytes are engineered to secrete IL-2 for self-sustenance, then cell survival should improve, but clinical trials showed no improvement over non-transduced lymphocytes
Solution Approach 1:
The invention combines multiple transgenes (IL-2, PD-1 decoy, and tEGFR) into a single lymphocyte construct, creating a synergistic system where each component addresses a different aspect of tumor microenvironment challenges. This combination approach overcomes the limitation of single-transgene engineering by providing comprehensive support for cell survival, immune activation, and resistance to suppression simultaneously.
Solution Approach 2:
The lymphocytes function as composite biological systems with multiple engineered components working together. The IL-2 provides growth support, the PD-1 decoy blocks immunosuppressive signals, and the tEGFR enables antibody-mediated depletion protection, creating a multi-functional cell therapy that addresses multiple limitations of previous approaches.
3Reliability
If solid tumors are treated with ACT therapy, then tumor cells can be targeted, but the immunosuppressive microenvironment prevents long-term functional persistence
Solution Approach 1:
The PD-1 decoy transgene provides preliminary protection against PD-1-mediated immunosuppression before the lymphocytes encounter suppressive signals in the tumor microenvironment. This preemptive blocking of the PD-1 pathway allows the cells to maintain their effector functions and resist exhaustion, directly countering the immunosuppressive mechanisms that normally limit long-term persistence in solid tumors.
Data Source
AI summary
The present disclosure relates to methods and compositions to confer and/or increase immune responses mediated by cellular immunotherapy, such as by adoptively transferring tumor-specific genetically-modified lymphocytes such as human T lymphocytes. The disclosure provides compositions comprising genetically-modified lymphocytes that express at least two transgene(s) having the ability to modulate the immune system and the innate and adaptive immune response.